2005
DOI: 10.1007/s00280-005-0118-0 View full text |Buy / Rent full text
|
|

Abstract: Hybrid biosynthetic approach produced a new anthracycline ID6105 (11-hydroxyaclacinomycin X, Hyrubicin), which has potent antitumor activities against a broad range of cancer cell lines. Like other anthracyclines, ID6105 has the inhibitory effects on DNA synthesis as well as topoisomerase II. As preclinical studies of ID6105, we investigated ID6105's efficacy on human tumors, and cardiotoxicity. In human tumor xenografts, the ID6105's antitumor effects were greater than other anticancer drugs. ID6105 induced t… Show more

Help me understand this report

Search citation statements

Order By: Relevance
Select...
1
0
2
0

Year Published

2017
2017
2019
2019

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

0
2
0
Order By: Relevance
“…However, the expenses associated with the use of this species limit its application in large‐scale molecular and/or therapeutic screening or modeling. To date, using a mouse model solely for drug screening (i.e., a single factor experimental study) is very rare, while multi‐factorial experiments have often been performed, for example, simultaneous evaluation of antitumor efficacy and cardiotoxicity of cancer drugs, and/or studies of cardioprotective strategies after using cancer drugs . More importantly, many drugs, including oncologic pharmaceuticals, can often lead to cardiotoxic electrophysiological effects (e.g., QT prolongation, atrioventricular conduction blocks, and ventricular arrhythmias including torsades do pointes); thus, adverse electrophysiological effects represent important phenotypes of drug‐induced cardiotoxicity .…”
Section: Research Gaps Challenges Perspectives and Opportunities Tmentioning
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1.2b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 7 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 130,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…However, the expenses associated with the use of this species limit its application in large‐scale molecular and/or therapeutic screening or modeling. To date, using a mouse model solely for drug screening (i.e., a single factor experimental study) is very rare, while multi‐factorial experiments have often been performed, for example, simultaneous evaluation of antitumor efficacy and cardiotoxicity of cancer drugs, and/or studies of cardioprotective strategies after using cancer drugs . More importantly, many drugs, including oncologic pharmaceuticals, can often lead to cardiotoxic electrophysiological effects (e.g., QT prolongation, atrioventricular conduction blocks, and ventricular arrhythmias including torsades do pointes); thus, adverse electrophysiological effects represent important phenotypes of drug‐induced cardiotoxicity .…”
Section: Research Gaps Challenges Perspectives and Opportunities Tmentioning
“…Apart from the famous doxorubicin family (e.g., daunorubicin, idarubicin, epirubicin, and so on, Figure A), aclacinomycin A (ALM-A, 1 ), isolated from Streptomyces galilaeus along with its analogs 2 – 4 (Figure A), has been marketed for the treatment of stomach, lung, ovarian carcinoma; malignant lymphoma; and acute leukemia. To develope optimized drug candidates, novel formulation and discovery of new derivatives about anthracyclines have received continuous attention in the past 40 years. …”
mentioning